Ownership
Private
Employees
~50
Therapeutic Areas
OncologyDermatology
Stage
Phase 3
Modalities
Small molecule

Peplin General Information

Lead candidate PEP005 (ingenol mebutate) gel completed first Phase 3 trial (REGION-I) for actinic keratosis in May 2009, with plans to complete additional Phase 3 trials by end of 2009. Phase 2 trials ongoing for basal cell carcinoma.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Emeryville, California
United States

Drug Pipeline

ingenol mebutate
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Peplin's pipeline data

Book a demo

Key Partnerships

LEO Pharma

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Peplin Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Peplin's complete valuation and funding history, request access »

Peplin Investors

Undisclosed private investors pre-IPO
Investor Type: Venture Capital
Holding: Minority